Last reviewed 2026-04-19 · How we verify

BENZOCTAMINE

Phase 2 active Small molecule

BENZOCTAMINE is a benzoctamine drug. It is currently in Phase 2 development.

Benzoctamine works by interacting with the central nervous system to produce a sedative and anxiolytic effect.

Benzoctamine is a small molecule drug in the benzoctamine class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, but it is used to treat various conditions. The commercial status of benzoctamine is unclear, and it may be patented or available as a generic medication. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacological properties and clinical applications.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENZOCTAMINE
Drug class	benzoctamine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a busy city with many thoughts and worries racing around. Benzoctamine helps calm down this activity by influencing the brain's chemistry, making it easier to relax and feel less anxious.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BENZOCTAMINE CI brief — competitive landscape report
BENZOCTAMINE updates RSS · CI watch RSS

Frequently asked questions about BENZOCTAMINE

What is BENZOCTAMINE?

BENZOCTAMINE is a benzoctamine drug.

How does BENZOCTAMINE work?

Benzoctamine works by interacting with the central nervous system to produce a sedative and anxiolytic effect.

What drug class is BENZOCTAMINE in?

BENZOCTAMINE belongs to the benzoctamine class. See all benzoctamine drugs at /class/benzoctamine.

What development phase is BENZOCTAMINE in?

BENZOCTAMINE is in Phase 2.

Drug class: All benzoctamine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing